Pdt Partners, LLC Gossamer Bio, Inc. Transaction History

Pdt Partners, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.21 - $14.88 $380,197 - $784,652	-52,732 Reduced 75.63%	16,996 $204,000
Q2 2022 Aug 15, 2022	SELL	$5.97 - $9.97 $185,213 - $309,309	-31,024 Reduced 30.79%	69,728 $584,000
Q1 2022 May 16, 2022	BUY	$8.44 - $12.49 $114,530 - $169,489	13,570 Added 15.57%	100,752 $875,000
Q4 2021 Feb 14, 2022	BUY	$10.12 - $14.07 $175,774 - $244,381	17,369 Added 24.88%	87,182 $986,000
Q3 2021 Nov 15, 2021	SELL	$7.25 - $13.23 $202,180 - $368,945	-27,887 Reduced 28.54%	69,813 $878,000
Q2 2021 Aug 16, 2021	SELL	$8.0 - $9.75 $120,960 - $147,420	-15,120 Reduced 13.4%	97,700 $793,000
Q1 2021 May 17, 2021	SELL	$8.63 - $10.94 $35,805 - $45,390	-4,149 Reduced 3.55%	112,820 $1.04 Million
Q4 2020 Feb 16, 2021	BUY	$8.3 - $13.59 $844,699 - $1.38 Million	101,771 Added 669.63%	116,969 $1.13 Million
Q3 2020 Nov 16, 2020	SELL	$11.3 - $14.75 $29,752 - $38,836	-2,633 Reduced 14.77%	15,198 $189,000
Q2 2020 Aug 14, 2020	BUY	$9.52 - $15.98 $169,751 - $284,939	17,831 New	17,831 $232,000

109

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $84.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.